詳細(xì)介紹
商品屬性:
產(chǎn)品名稱 | 規(guī)格 | 貨號(hào) |
SH2結(jié)構(gòu)含磷酸肌醇SHIP1抗體 | 50ul、100ul、200ul | CS-A3915 |
商品詳情:
英文名稱:SHIP1
別 名:Inositol polyphosphate 5 phosphatase of 145kDa; 4; 5-trisphosphate 5-phosphatase 1; hp51CN; hSHIP; Inositol polyphosphate 5 phosphatase 145kDa; Inositol polyphosphate 5 phosphatase; Inositol polyphosphate 5 phosphatase D; Inositol polyphosphate-5-phosphatase of 145 kDa; INPP 5D; INPP5D; INPP5D protein; MGC104855; MGC142140; MGC142142; p150 ship; p150Ship; Phosphatidylinositol 3,4,5 trisphosphate 5 phosphatase 1; Phosphatidylinositol-3; SH2 containing inositol 5 phosphatase; SH2 containing inositol phosphatase isoform b; SH2 domain containing inositol 5' phosphatase 1; SH2 domain containing inositol phosphatase 1; SH2 domain-containing inositol phosphatase 1; SH2 domain-containing inositol-5''-phosphatase 1; SHIP 1; SHIP-1; SHIP1; SHIP1_HUMAN; Signaling inositol polyphosphate 5 phosphatase SIP 145; Signaling inositol polyphosphate 5 phosphatase SIP145; SIP 145; SIP-145; SIP145.
研究領(lǐng)域:免疫學(xué) 信號(hào)轉(zhuǎn)導(dǎo) 激酶和磷酸酶 t-淋巴細(xì)胞
抗體來(lái)源:Rabbit
克隆類型:Polyclonal
交叉反應(yīng):Human, Mouse, (predicted: Rat, Pig, Cow, Horse, )
產(chǎn)品應(yīng)用:WB=1:500-2000 ELISA=1:5000-10000
not yet tested in other applications.
optimal dilutions/concentrations should be determined by the end user.
理論分子量:133kDa
細(xì)胞定位:細(xì)胞漿 細(xì)胞膜
性 狀:Liquid
濃 度:1mg/ml
免 疫 原:KLH conjugated synthetic peptide derived from human SHIP1: 701-800/1189
亞 型:IgG
純化方法:affinity purified by Protein A
緩 沖 液:0.01M TBS(pH7.4) with 1% BSA, 0.03% Proclin300 and 50% Glycerol.
注意事項(xiàng):This product as supplied is intended for research use only, not for use in human, therapeutic or diagnostic applications.
產(chǎn)品介紹:SHIP1 is a member of the inositol polyphosphate-5-phosphatase (INPP5) family and contains an N-terminal SH2 domain, an inositol phosphatase domain, and two C-terminal protein interaction domains. Expression of this protein is restricted to hematopoietic cells where its movement from the cytosol to the plasma membrane is mediated by tyrosine phosphorylation in response to multiple cytokine and B and T cell receptor activation. At the plasma membrane, the protein hydrolyzes the 5' phosphate from phosphatidylinositol (3,4,5)-trisphosphate and inositol-1,3,4,5-tetrakisphosphate, thereby affecting multiple signaling pathways. Overall the protein functions as a negative regulator of myeliod cell proliferation and survival.
Phosphatidylinositol (PtdIns) phosphatase that specifically hydrolyzes the 5-phosphate of phosphatidylinositol-3,4,5-trisphosphate (PtdIns(3,4,5)P3) to produce PtdIns(3,4)P2, thereby negatively regulating the PI3K (phosphoinositide 3-kinase) pathways. Acts as a negative regulator of B-cell antigen receptor signaling. Mediates signaling from the FC-gamma-RIIB receptor (FCGR2B), playing a central role in terminating signal transduction from activating immune/hematopoietic cell receptor systems. Acts as a negative regulator of myeloid cell proliferation/survival and chemotaxis, mast cell degranulation, immune cells homeostasis, integrin alpha-IIb/beta-3 signaling in platelets and JNK signaling in B-cells. Regulates proliferation of osteoclast precursors, macrophage programming, phagocytosis and activation and is required for endotoxin tolerance. Involved in the control of cell-cell junctions, CD32a signaling in neutrophils and modulation of EGF-induced phospholipase C activity. Key regulator of neutrophil migration, by governing the formation of the leading edge and polarization required for chemotaxis. Modulates FCGR3/CD16-mediated cytotoxicity in NK cells. Mediates the activin/TGF-beta-induced apoptosis through its Smad-dependent expression. May also hydrolyze PtdIns(1,3,4,5)P4, and could thus affect the levels of the higher inositol polyphosphates like InsP6.
實(shí)驗(yàn)原理 :
(1)公司產(chǎn)品僅用于科研特異性結(jié)合抗原:抗體本身不能直接溶解或殺傷帶有特異抗原的靶細(xì)胞,通常需要補(bǔ)體或吞噬細(xì)胞等共同發(fā)揮效應(yīng)以清除病原微生物或?qū)е虏±頁(yè)p傷。然而,抗體可通過(guò)與病毒或毒素的特異性結(jié)合,直接發(fā)揮中和病毒的作用。
(2)活補(bǔ)體:IgM、IgG1、IgG2和IgG3可通過(guò)經(jīng)典途徑激活補(bǔ)體,凝聚的IgA、IgG4和IgE可通過(guò)替代途徑激活補(bǔ)體。
(3)結(jié)合細(xì)胞:不同類別的免疫球蛋白,可結(jié)合不同種的細(xì)胞,參與免疫應(yīng)答。
(4)可通過(guò)胎盤及粘膜:免疫球蛋白G(IgG)能通過(guò)胎盤進(jìn)入胎兒血流中,使胎兒形成自然被動(dòng)免疫。免疫球蛋白A(IgA)可通過(guò)消化道及呼吸道粘膜,是粘膜局部抗感染免疫的主要因素。
(5)具有抗原性:抗體分子是一種蛋白質(zhì),也具有刺機(jī)體產(chǎn)生免疫應(yīng)答的性能。不同的免疫球蛋白分子,各具有不同的抗原性。
(6)抗體對(duì)理化因子的抵抗力與一般球蛋白相同:不耐熱,60~70℃即被破壞。各種酶及能使蛋白質(zhì)凝固變性的物質(zhì),均能破壞抗體的作用??贵w可被中性鹽類沉淀。在生產(chǎn)上??捎昧蛩徜@或硫酸鈉從免疫血清中沉淀出含有抗體的球蛋白,再經(jīng)透析法將其純化。
一抗和二抗的區(qū)別:
第一抗體就是平常所說(shuō)的抗體,即能和抗原特異性結(jié)合。
第二抗體是能和抗體結(jié)合的,即抗體的抗體。主要用于檢測(cè)抗體的存在。
一抗是針對(duì)抗原的抗體,二抗是針對(duì)一抗的抗體。即抗體也可以充當(dāng)抗原刺激機(jī)體產(chǎn)生抗體。也就是說(shuō),抗原進(jìn)入機(jī)體刺激機(jī)體免疫系統(tǒng)產(chǎn)生免疫應(yīng)答,由B細(xì)胞可以產(chǎn)生與相應(yīng)抗原發(fā)生特異性結(jié)合的特殊蛋白質(zhì)。
一抗二抗都是一種可以特異結(jié)合別的物質(zhì)的基團(tuán),而且一抗可以至少結(jié)合兩種其他基團(tuán)(底物和二抗)。
一抗:可以特異結(jié)合底物,就是識(shí)別出我們想要檢測(cè)的東西。一抗和底物結(jié)合與否用肉眼是看不出來(lái)的。
二抗:可以和一抗結(jié)合,并帶有可以被檢測(cè)出的標(biāo)記(如帶熒光、放射性、化學(xué)發(fā)光或顯色基團(tuán)),作用是檢測(cè)一抗。 如果一抗自己帶有可以被檢測(cè)出的標(biāo)記(如帶熒光、放射性、化學(xué)發(fā)光或顯色基團(tuán)),則不需要二抗。但這樣成本很高,因?yàn)橐环N一抗只識(shí)別一種底物。所以如今的設(shè)計(jì)一般是二抗帶上可檢測(cè)標(biāo)記,再來(lái)檢測(cè)一抗。而一抗識(shí)別底物。這樣,當(dāng)一抗結(jié)合到底物上,就可以通過(guò)二抗檢測(cè)出來(lái)。
公司正在出售的產(chǎn)品:
凋亡抑制因子IASPP封閉多肽 | 牛巴貝斯蟲PCR試劑盒 |
20號(hào)染色體開放閱讀框194封閉多肽 | 禽腺病毒通用PCR檢測(cè)試劑盒 |
轉(zhuǎn)錄因子Tbx5封閉多肽 | 庫(kù)蚊通用PCR檢測(cè)試劑盒 |
20號(hào)染色體開放閱讀框96封閉多肽 | 車前子探針法PCR鑒定試劑盒 |
染色盒同源物4封閉多肽 | 羊闊盤吸蟲PCR試劑盒 |
白介su1β/IL-1β封閉多肽 | 尤氏泰勒蟲PCR檢測(cè)試劑盒 |
PDZ連接激mei/T-LAK細(xì)胞源蛋白激mei封閉多肽 | 腸賈第蟲PCR試劑盒 |
尿苷二磷suan葡萄糖醛suan轉(zhuǎn)移mei2B4封閉多肽 | 齒垢密螺旋體PCR檢測(cè)試劑盒 |
磷suan化致癌基因C-Myc封閉多肽 | 鸚鵡熱衣原體PCR試劑盒 |
透明帶結(jié)合蛋白封閉多肽 | 禽阿爾法皰疹病毒型=馬立克病病毒PCR檢測(cè)試劑盒 |
人運(yùn)甲狀腺su蛋白/前白蛋白(TTR)ELISA試劑盒 | 微管多特異性有機(jī)陰離子轉(zhuǎn)運(yùn)蛋白2ELISA試劑盒 |
人低氧誘導(dǎo)因子1α(HIF-1α)ELISA檢測(cè)試劑盒 | Dachsous2蛋白ELISA試劑盒 |
白(Hb)試劑盒ELISA | 抗醛縮meiELISA試劑盒 |
SH2結(jié)構(gòu)含磷酸肌醇SHIP1抗體大鼠結(jié)蛋白(Des)ELISA Kit | DnaJ/Hsp40同源物亞家族C成員12ELISA試劑盒 |
腎綜合癥出血熱病毒RT-PCR試劑盒 | GATA結(jié)合蛋白3ELISA試劑盒 |
抗體的標(biāo)記實(shí)驗(yàn)要點(diǎn):
1.如在反應(yīng)混合液中有疊氮鈉或游離氨基存在,會(huì)抑制標(biāo)記反應(yīng)。因此,蛋白質(zhì)在反應(yīng)前要對(duì) 0.1mol/L緩沖液或0.5mol/L硼酸緩沖液充分透析;
2.所用的NHSB及待化蛋白質(zhì)之間的分子比按蛋白質(zhì)表面的ε-氨基的密度會(huì)有所不同,選擇不當(dāng)則影響標(biāo)記的效率,應(yīng)先用幾個(gè)不同的分子比來(lái)篩選最適條件;
3.用NHSB量過(guò)量也是不利的,抗原的結(jié)合位點(diǎn)可能因此被封閉,導(dǎo)致抗體失活;
4.由于抗體的氨基不易接近可能造成化不足,此時(shí)可加入去污劑如 Triton x-100, Tween20等;
5.當(dāng)游離ε-氨基(賴氨酸殘基的氨基)存在于抗體的抗原結(jié)合位點(diǎn)時(shí),或位于酶的催化位點(diǎn)時(shí),化會(huì)降低或損傷抗體蛋白的結(jié)合力或活性;
6.還可能與不同的功能基團(tuán),如羰基、氨基、巰基、異咪唑基及基,也可與糖基共價(jià)結(jié)合;
7.交聯(lián)反應(yīng)后,應(yīng)充分透析,否則,殘余的會(huì)對(duì)化抗體與親和素的結(jié)合產(chǎn)生競(jìng)爭(zhēng)作用;
8.在細(xì)胞的熒光標(biāo)記實(shí)驗(yàn)中,中和親和素的本底低,但由于鏈霉親和素含有少量正電荷,故對(duì)某些細(xì)胞可導(dǎo)致高本底。